In Brief: Cardiovascular Dynamics
This article was originally published in The Gray Sheet
Executive SummaryCardiovascular Dynamics: FDA approves PMA supplement for its FACT-22 (Focus Angioplasty Catheter Technology) and ARC-22 (Active Response Catheter) coronary balloon angioplasty catheters. The products feature longer balloon inflation lengths (22 mm), "which expand the clinical applications and potential market" for CVD's Focus technology, the company says. CVD gained approval in January for the original version of its FACT catheter; an original version of the ARC was approved in June. CVD's Focus technology provides users "both low and high balloon inflation pressures within a single catheter," the company says. CVD plans to launch the new FACT-22 and ARC-22 versions at the scientific sessions of the American Heart Association in November...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.